Consolidated Basic Cancer Research Program

项目总结--总体 Wistar癌症中心的愿景是通过杰出的研究、教育和 合作伙伴关系，其使命是将基础的、翻译的和以患者为导向的癌症研究融合在一个 单一科学连续体。在2013年更新癌症中心时被评为特殊(影响评分，19分) 支持赠款(CCSG)，癌症中心继续走在科学卓越的道路上，影响深远 在基础和转化型癌症研究方面的贡献，以及与邻近国家富有成效的伙伴关系 学术机构。利用2014年福克斯研究塔的开放，这是建造在 Wistar园区，一个以科学为重点的领导层，那里的癌症中心主任(Dr.Altieri)也是研究所 总裁兼首席执行官(CEO)和一个灵活、机会驱动的管理机构--癌症 中心在上一个CCSG预算周期中招募了10名新成员，扩大了技术能力 在所有共享资源中，并重新调整计划，以实现最佳的科学影响和协作。它的基础 研究成果阐明了染色质组织中肿瘤发生的基本基础， 非编码RNA、局部免疫抑制和转移能力，而特定于疾病部位的主题 在黑色素瘤和卵巢癌中，从定义新的致癌途径到解开 将新的治疗药物引入临床的耐药机制。在这样的背景下，巨蟹座 该中心目前获得了1240万美元的同行评议的癌症相关资金，其中890万美元来自NCI 对于76%的特殊癌症焦点。癌症中心的三个项目在 独特的癌症研究协作方法：76%的同行评审资金和超过40%的 这些项目中的“发现”出版物目前是多名研究人员合作的产物。为. 癌症中心只有27名成员，Wistar现在为三个专门的研究项目做出贡献 优秀奖(孢子)，五个项目项目奖助金，六个多重PI奖，四个U型奖助金。这个 癌症中心将其基本发现转移到临床的总体目标已经实现了一个里程碑式的目标 与海伦·F·格雷厄姆癌症中心(HFGCC)达成协议，这是美国第一个将 NCI赞助的两个项目：NCI指定的基础癌症中心(Wistar)和 NCI社区肿瘤学研究计划(HFGCC)。这使得有效的协作成为可能 Wistar科学家和HFGCC临床医生之间的合作，为社区带来了尖端的癌症研究。这个 癌症中心将在下一次CCSG预算期间继续取得这一成功的成就 周期，在基础和翻译肿瘤免疫学方面创造新的多学科研究主题，早期- 学术药物发现阶段，肿瘤新陈代谢研究阶段。作为一种 Wistar是一个专门致力于生物医学发现的组织，它独特地准备继续 基础性、转化性和以患者为中心的癌症研究的变革性进展。

PROJECT SUMMARY – OVERALL The vision of the Wistar Cancer Center is to conquer cancer through outstanding research, education and partnership, and its mission is to merge basic, translational, and patient-oriented cancer research in a single scientific continuum. Rated Exceptional (Impact score, 19) at the 2013 renewal of the Cancer Center Support Grant (CCSG), the Cancer Center has continued on a path of scientific excellence, impactful contributions in basic and translational cancer research, and productive partnerships with neighboring academic Institutions. Leveraging the 2014 opening of the Fox Research Tower, the largest building built on Wistar campus, a science-focused leadership where the Cancer Center Director (Dr. Altieri) is also Institute President and Chief Executive Officer (CEO) and a nimble, opportunity-driven administration, the Cancer Center has recruited 10 new members during the last CCSG budget cycle, expanded technological capabilities in all Shared Resources, and realigned Programs for optimal scientific impact and collaboration. Its basic research contributions have elucidated fundamental underpinnings of tumorigenesis in chromatin organization, non-coding RNA, local immunosuppression and metastatic competence, whereas disease site-specific themes in melanoma and ovarian cancer have run the gamut from defining new oncogenic pathways to unraveling mechanisms of drug resistance to bringing novel therapeutics to the clinic. Against this backdrop, the Cancer Center currently receives $12.4 million in peer-reviewed, cancer-related funding, with $8.9 million from the NCI for an exceptional cancer focus of 76%. The three Programs in the Cancer Center have succeeded in a uniquely collaborative approach to cancer research: 76% of all peer-reviewed funding and over 40% of “discovery” publications in the Programs are currently the product of multi-investigator collaborations. For a Cancer Center with only 27 members, Wistar now contributes to three Specialized Programs of Research Excellence (SPOREs), five Program Project grants, six multi-PI awards, and four U-type grants. The overarching goal of the Cancer Center to move its basic discoveries to the clinic has been met with a landmark agreement with the Helen F. Graham Cancer Center (HFGCC), the first partnership in the nation to bring together two NCI-sponsored programs: an NCI-designated “basic” Cancer Center (Wistar) and a member of the NCI Community Oncology Research Program (HFGCC). This has enabled impactful collaborations between Wistar scientists and HFGCC clinicians, bringing cutting-edge cancer research to the community. The Cancer Center will continue on this successful trajectory of accomplishments during the next CCSG budget cycle, creating new, multidisciplinary research themes in basic and translational tumor immunology, early- stage academic drug discovery, and exploitation of tumor metabolism for novel cancer therapeutics. As an organization solely dedicated to biomedical discovery, Wistar is uniquely poised to continue making transformative advances in basic, translational, and patient-focused cancer research.